When fine chemical firms flirt with drug delivery

By Gregory Roumeliotis

- Last updated on GMT

Related tags Drug delivery Pharmacology

Pharmaceutical excipients can have a profound impact on the release
profile of drugs, driving fine chemical companies to raise their
game since they realise their clients see excipients as more than
inactive ingredients.

At the Controlled Release Society's annual meeting in Vienna, specialty chemical companies were out in full force to convince drug manufacturers that their excipients do not just facilitate production but also enhance the efficacy of drugs through controlled release.

Some companies are discovering that raw materials that have been traditionally used as solvents or excipients have interesting drug delivery properties.

Gaylord, for example, has been supplying the pharma industry with dimethyl sulfoxide (DMSO) for years, establishing itself as the biggest provider of DMSO in the world.

DMSO is used as a solvent in which active pharmaceutical ingredients (APIs) are made.

But lately Gaylord has been making DMSO of United States Pharmacopoeia (USP) grade because it has been shown that when it is included in transdermal formulations, it enhances the permeation of many APIs through human skin.

"If you look at the skin permeation of tetracaine or lidocaine with DMSO, you will see the uptake is rapid," Artie McKim, Gaylord's director of technology, told In-PharmaTechnologist.com.

"This is a drug-specific issue though, it is difficult to predict the exact classes of drugs DMSO works with well in transdermal delivery."

Other specialty chemical firms go beyond selling excipients as components of drug delivery and develop their own delivery technologies which they license to drugmakers.

A case in point is Degussa; the company has developed three oral drug delivery technologies - Eudrapulse, Eudracol and Eudramode - based on its polymers that can achieve various release profiles lasting up to 24 hours.

"We wanted to be more than an excipient provider and be closer to our customers, offering them complete drug delivery solutions," Gerhard Renner, director of technologies at Degussa Pharma Polymers, told In-PharmaTechnologist.com.

"We started pushing these technologies in 2003 and we have seen a lot of interest from companies looking to license them."

Other fine chemical firms are more conservative.

It is interesting that BASF has highly functional polymers like Degussa that it uses in solid oral dosage forms and a range of coatings - instant release, sustained release and enteric coatings.

Yet unlike Degussa, BASF has not yet brought its own drug delivery technologies to the market.

"Our innovative coating polymer Kollicoat in combination with sustained release coatings allows for new principles of drug delivery and of course we thoroughly explore business opportunites which will come along with these developments," BASF's head of business development, Christof Kandzia, told In-PharmaTechnologist.com.

"We are very pleased with the accelerating growth of our new Kollicoat coatings line and despite their long history, our PVP-based Kollidon grades are still growing driven by strong customer demand."

As drug delivery emerges as a lucrative market, specialty chemical firms are set to intensify their efforts to develop new functional excipients and even drug delivery technologies, resulting in one major beneficiary - the drug manufacturer.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us